Randomised controlled studies, including the “Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity” (BEAT-ROP) [10] and the “RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity” (RAINBOW) [11], have investigated the effectiveness of anti-vascular endothelial growth factor (VEGF) agents for treatment. Here, VEGFA is linked to retinopathy of prematurity.